KIF18A Targeting Therapies FDA EMA Approval Clinical Trials By Indication Company Country Drug Class Report
Highest Phase Of Development: Phase-I/II
KIF18A Targeting Therapies In Clinical Trials: > 10 Therapies
KIF18A Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
KIF18A Targeting Therapies Market Development Trends Insight
KIF18A Therapies Technology Platforms Insight
Download Report: https://www.kuickresearch.com/report-kif18a-targeting-inhibitor-kif18a-inhibitor-clinical-trials-kif18a-targeting-therapy
The global KIF18A targeting therapies market is rapidly gathering momentum as KIF18A has emerged as a key vulnerability in cancers characterized by chromosomal instability. As a mitotic kinesin motor protein essential for chromosome alignment during cell division, KIF18A is overexpressed in malignancies such as ovarian and triple-negative breast cancers, making it a promising target for precision oncology with potentially lower toxicity than traditional chemotherapies.
Although no KIF18A-targeted therapy is commercially available yet, the field is progressing quickly. Clinical pipelines include more than 10 therapies, with several in early clinical development. Among the frontrunners is ATX‑295 from Accent Therapeutics, an oral, best-in-class small-molecule inhibitor that recently entered a Phase I/II dose-escalation study in patients with advanced solid tumors, including ovarian and triple-negative breast cancer. It's employed with biomarker-enriched enrollment based on genomic instability markers like whole-genome doubling, and has received FDA Fast Track status—accelerating its path forward.
The clinical landscape includes global contributions from leading biotechs such as Volastra Therapeutics, advancing multiple small-molecule inhibitors including Sovilnesib (AMG‑650) in Phase I for platinum-resistant ovarian cancer, and VLS‑1488 in Phase I/II across chromosomal instability-high tumors. Accent's ATX‑295 stands currently at the most advanced Phase I/II stage, with trials in the US and potentially Asia-Pacific, suggesting geographic development convergence.
Technological innovation underpins expansion in this field. Development is dominated by small-molecule inhibitors designed to halt KIF18A's motor activity at kinetochores, causing mitotic catastrophe in cancer cells. Alternative approaches include disrupting upstream regulatory pathways like phosphorylation, and leveraging AI-driven drug discovery platforms. For example, Insilico Medicine's Chemistry42 and PandaOmics platforms generated a macrocyclic KIF18A inhibitor (ISM9682), showcasing the power of AI to enhance specificity and efficiency in drug design.
Market trends demonstrate strong growth potential. The first commercial KIF18A-targeting therapy is expected by 2030, propelled by fast track designations and positive preclinical data. The rich pipeline, combined with precision biomarker strategies, supports a robust developmental roadmap, aligning with unmet clinical needs in CIN-high solid tumors and potentially extending to hematologic malignancies where KIF18A overexpression correlates with poor prognosis.
Regional development trends show clinical leadership based in the US and Europe, where companies like Accent and Volastra are active, while China and other Asia-Pacific markets are engaging through global trial participation and local biotech collaborations. Multi-region trial footprints and biomarker-defined patient enrollment strategies are shaping global development dynamics.
Our Global KIF18A Targeting Therapies Market Report offers detailed insights into this evolving therapeutic area. It profiles more than ten clinical-stage candidates by company, indication, country, and development phase, with a deep focus on ATX‑295 as the leading Phase I/II program. The report evaluates technology platforms, including small-molecule motor inhibitors and AI-enabled discovery, and analyzes biomarker-led patient selection models. Regional development trends and regulatory environments are mapped, and strategic partnerships and investments are examined.
For pharmaceutical executives, biotech investors, and drug development leaders, this report provides a strategic foundation. It outlines market drivers, technological innovations, and clinical milestones that are poised to transform KIF18A from a promising target into an approved therapeutic by 2030, potentially offering new treatment options for patients with chromosomally unstable tumors.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
39 minutes ago
- Business Wire
PursueCare to Showcase Digital-First Addiction Treatment and Collaborative Care Models at 2025 Behavioral Health Business Addiction Treatment Forum in Chicago
MIDDLETOWN, Conn.--(BUSINESS WIRE)-- PursueCare, a virtual clinic for substance use disorder (SUD) treatment, will participate in a panel exploring partnerships and strategies for integrated, whole-person care models in behavioral health at the 2025 Behavioral Health Business (BHB) Addiction Treatment Forum in Chicago, Ill., on July 17, 2025, at Convene (311 W Monroe). The forum also spotlights current investment and operational trends shaping the addiction treatment industry. Available across Connecticut, Kentucky, Massachusetts, Maine, Ohio, and West Virginia, PursueCare delivers comprehensive, virtual-first SUD care that bridges the gaps in access and continuity of care. Share Nicholas Mercadante, Founder and CEO of PursueCare, will join the expert panel titled 'Who's at Quarterback? Ensuring Smooth SUD Handoffs and Building the Partnership Playbook,' slated for 11:30 a.m. CDT. Mercadante will discuss the critical importance of integrated care models and effective handoffs in SUD treatment, drawing on his experience leading a tech-enabled platform designed to meet patients where they are—with convenience, compassion, and clinical excellence. As a former healthcare attorney turned entrepreneur, Mercadante founded PursueCare with a mission to dismantle barriers to addiction treatment by leveraging technology, innovative care delivery, and cross-sector partnerships. Under his leadership, PursueCare has become a leading voice in redefining how providers, payors, and care networks collaborate to treat SUDs holistically. 'Everyone of us at PursueCare is committed to value-based care, our team is dedicated to serving patients in need and shaping industry standards around quality, accessibility, and equity.' Innovation in Action: How PursueCare Is Transforming Addiction Treatment PursueCare delivers comprehensive, virtual-first SUD care that bridges the gaps in access and continuity of care. Available across Connecticut, Kentucky, Massachusetts, Maine, Ohio, and West Virginia, the platform offers: Multidisciplinary care teams include addiction medicine providers, counselors, psychiatrists, and pharmacists. FDA-authorized digital therapeutics — RESET ® and RESET-O ® —that support recovery 24/7 through interactive cognitive behavioral therapy. Integrated pharmacy and lab services through PursueCareRx, enabling seamless medication management and compliance monitoring. Flexible access through a HIPAA-compliant app with support for both scheduled and on-demand visits. Broad insurance acceptance, including Medicare, Medicaid, and most private plans. Mercadante will share the virtual clinic's approach to forging strong partnerships with health systems, employers, and value-based care organizations—offering seamless care coordination, real-time engagement, and outcome-driven models that empower both patients and partners. He'll be joined by fellow industry pioneers Jamie Vinck, President of Meadows Behavioral Health; Beth Keeney, CEO of LifeSpring Health Systems; and Dr. Ayesha Appa, Assistant Professor of Medicine at the University of California, San Francisco. The BHB Forum will offer behavioral health professionals the opportunity to connect, collaborate, and learn from leaders and innovators across the industry. Attendees will include behavioral health professionals, investors, creators, and a range of vendors and service providers. About PursueCare PursueCare provides personalized virtual addiction treatment for individuals across states (CT, KY, MA, ME, OH, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET ® and RESET-O ®, supports recovery 24/7. We accept private insurance, Medicare, and Medicaid. For full disclaimers please visit .
Yahoo
an hour ago
- Yahoo
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
Atara Biotherapeutics Resubmits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease to the U.S. FDA Approval of BLA Would Trigger $40 Million Milestone Payment from Pierre Fabre Laboratories THOUSAND OAKS, Calif., July 14, 2025--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO™ or tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. There are no FDA approved therapies in this treatment setting. "The BLA resubmission for tab-cel represents the collaborative efforts with our partner, Pierre Fabre Laboratories, to address the third-party manufacturing facility observations outlined in the January 2025 Complete Response Letter," said Cokey Nguyen, President and Chief Executive Officer of Atara. "We look forward to continued engagement with the FDA throughout its review and with Pierre Fabre Laboratories as they actively prepare for the potential launch of this innovative therapy in the U.S." Tab-cel is an allogeneic, EBV-specific T-cell immunotherapy designed to target and eliminate EBV-infected cells. The BLA is supported by pivotal and supportive data covering more than 430 patients treated with tab-cel across multiple life-threatening diseases, including the latest pivotal ALLELE study data that demonstrated a statistically significant 48.8% Objective Response Rate (ORR) (p<0.0001) and favorable safety profile consistent with previous analyses. Tab-cel has been granted Breakthrough Therapy Designation for the treatment of rituximab-refractory EBV-associated lymphoproliferative disease by the U.S. FDA and has orphan drug designation for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders. Corporate Updates Tab-cel Transition Activities: The company is finalizing the transfer of the following clinical studies associated with tab-cel: NCT03394365: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) NCT04554914: A Study to Evaluate Tabelecleucel in Participants with Epstein-Barr Virus-associated Diseases. This study is a multicenter, multicohort, open-label, single-arm, Phase 2 study investigating the efficacy and safety of tabelecleucel for the treatment of EBV-associated diseases. Upon completion substantially all operational activities and associated costs related to tab-cel will transfer to Pierre Fabre Laboratories. The sponsorship of the BLA continues to be maintained by Atara. Cash Runway and Future Tabelecleucel (Tab-cel®) Milestone and Royalty Income: Atara projects that its cash, cash equivalents and short-term investments of approximately $22M as of June 30, 2025, combined with the cost reduction initiatives implemented in the first half of 2025, will enable funding of all currently planned operations, including one-time restructuring costs, into the first quarter of 2026, that Atara believes will be sufficient to fund the ongoing activities required to achieve potential BLA approval. Additionally, under its commercialization agreement with Pierre Fabre Laboratories, Atara is eligible to receive a $40 million milestone payment upon FDA approval of the tab-cel BLA, as well as significant double-digit tiered royalties as a percentage of net sales, and milestones related to commercial sales of EBVALLO. The estimate of our cash, cash equivalents and short-term investments as of June 30, 2025, is preliminary, has not been audited and it is subject to change upon completion of our financial statement closure procedures. Our independent registered public accounting firm has not audited or completed any procedures with respect to this estimate. Such estimates are based on assumptions and plans that are subject to change and such changes could materially impact our expected cash runway. These assumptions include the completion of specific development and regulatory activities by us and actions taken by third parties, and are, therefore, uncertain at this time. Any delay in these activities will create additional expenses and cash needs for us. We have not yet completed our quarter-end financial close process for the quarter ended June 30, 2025. This estimate of our cash, cash equivalents and short-term investments as of June 30, 2025, is preliminary and is subject to change upon completion of our financial statement closing procedures. Additional information and disclosure would be required for a more complete understanding of our financial position and results of operations as of and for the quarter ended June 30, 2025. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit and follow @Atarabio on X and LinkedIn. Forward-Looking Statements This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the resubmission of the BLA and potential indications, the timing for FDA review of any resubmission of the BLA, the potential characteristics and benefits of tab-cel, and the results of, and prospects for, the global partnership with Pierre Fabre Laboratories involving tab-cel, and the potential financial benefits to Atara as a result of the global partnership with Pierre Fabre Laboratories, including the receipt, timing and amount of any payments to be received by Atara thereunder; (2) Atara's estimate of its cash, cash equivalents, and short-term investments as of June 30, 2025, as well as Atara's cash runway, receipt of potential milestone payments, and operating expenses, including Atara's ability to fund its planned operations into the first quarter of 2026; and (3) Atara's planned transition of substantially all remaining activities relating to tab-cel to Pierre Fabre Laboratories and the timing thereof. Because such statements deal with future events and are based on Atara's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks related with the timing of the transfer of substantially all operational activities related to tab-cel to Pierre Fabre Laboratories, with any potential delay creating additional expenses and cash needs for Atara; risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA feedback and the ability of Atara, Pierre Fabre Laboratories and Pierre Fabre Laboratories third-party manufacturer to address issues identified in the Complete Response Letter (CRL); our ability to access capital, and the sufficiency of Atara's cash resources and access to additional capital on favorable terms or at all; risks and uncertainties related to Atara's financial close and audit procedures; and other risks and uncertainties affecting Atara, including those discussed in Atara's filings with the Securities and Exchange Commission, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. View source version on Contacts Investor and Media Relations Amber DaughertySr. Director, Strategy and Operationsadaugherty@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
GoGoGrandparent Accepted into the AgeTech Collaborative™ from AARP Accelerator Program
GoGoGrandparent SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- GoGoGrandparent, the first on-demand ride, delivery and care services designed to help aging adults continue to live independently, today announced it has been accepted into the AgeTech Collaborative™ from AARP accelerator program, an 8-week program designed to elevate promising early-stage AgeTech startups. Baby Boomers are now beginning to reach the age of becoming grandparents. According to the National Council on Aging: 'With people in the U.S. aging better and living longer, older adults are one of the fastest-growing groups in the country. In fact, by 2030, all Baby Boomers will be age 65+ and by 2040 roughly 78.3 million Americans will fall within that age group.' GoGo's mission is to help this growing population of seniors live independently in their homes longer. With GoGo, there is no need for a smartphone or app. Seniors can use a landline to call and select GoGo's suite of 24/7 concierge services including rides, meal delivery, grocery shopping, house cleaning, medication delivery, companions, pet services and more. GoGo screens drivers ahead of time to make sure their vehicles are accessible, and drivers are willing to assist riders as needed (for instance, with walkers or wheelchairs). In addition to transportation, GoGoGrandparent also provides delivery, care and home services. 'We are thrilled to be selected to the AgeTech Collaborative from AARP Accelerator Program and join a great cohort of companies dedicated to helping seniors improve the quality of their life and live independently as they age,' said Justin Boogaard, GoGoGrandparent CEO and Founder. 'GoGo is making a meaningful impact on hundreds of thousands of seniors all over the country, and we are excited to grow our services with the mentorship of the AgeTech Collaborative.' About GoGoGrandparent GoGoGrandparent provides the first on-demand ride, delivery and care services designed to help aging adults continue to live independently. Clients select GoGo's suite of 24/7 concierge services including rides, meal delivery, grocery shopping, house cleaning, medication delivery, companions, pet services and more via a simple phone call, no smartphone or app required. GoGo works with partners including Uber, Instacart, DoorDash, TaskRabbit, Walmart, Amazon, and vetting drivers, vehicles and companions to make sure they can accommodate the needs of seniors. Built in 2016 and inspired by the CEO's grandmother, GoGo is relied upon by hundreds of thousands of people and available in all 50 states as well as Canada and Australia. Learn more at Media contact:Kerry MetzdorfBig Swing 978-609-0766 A photo accompanying this announcement is available at
